{
  "abstract": "The US Food and Drug Administration has approved the weight loss drug semaglutide, marketed as Wegovy, for the treatment of patients with a severe form of liver disease called metabolic associated steatohepatitis (MASH) and moderate to advanced fibrosis scarring.1",
  "authors": [
    {
      "affiliations": [
        "The BMJ"
      ],
      "name": "Kate Bowie"
    }
  ],
  "title": "Semaglutide: FDA approves weight loss jab to treat severe liver disease",
  "uid": "4cc10bbc-728b-5bcc-b103-998c6d21a5f1"
}